Rewiring of the N-Glycome with prostate cancer progression and therapy resistance
William Butler(Duke University), Jiaoti Huang(Space Science Institute), Daniel J. George(Duke University), Richard R. Drake(Medical University of South Carolina), Colin T. McDowell(Medical University of South Carolina), Yinglu Zhou(Dana-Farber Cancer Institute), J. Spencer Hauck(Duke University), Hong Zhang(Duke University), Yiping He(Dalian University of Technology), Qing Yang(Guangzhou University of Chinese Medicine), Yue Zhao(Jiangsu Provincial Center for Disease Control and Prevention), Andrew J. Armstrong(Duke University)
Cited by 22
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k